Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches.

COVID-19 vaccines Pharmacovigilance South Africa surveillance vaccine safety

Journal

Expert opinion on drug safety
ISSN: 1744-764X
Titre abrégé: Expert Opin Drug Saf
Pays: England
ID NLM: 101163027

Informations de publication

Date de publication:
08 Aug 2024
Historique:
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: aheadofprint

Résumé

Despite the public health success of vaccination, there is an ongoing need to build public confidence in vaccines and improve systems to monitor safety while maintaining data security and patient privacy. African countries face multiple challenges in establishing systems for vaccine pharmacovigilance as was demonstrated during COVID-19 mass vaccination. We provide a framework for the development of pharmacovigilance using the COVID-19 vaccination roll-out as an exemplar. We describe the pre-COVID-19 vaccine pharmacovigilance systems in Southern Africa and propose improvements based on our experience of COVID-19 vaccine roll-out in South Africa where we implemented systems to evaluate real-world safety and effectiveness of COVID-19 vaccinations. By conducting a pubmed review of the literature on pharmacovigilance with a focus on Africa and from guidance emanating from the World Health Organisation (WHO), we evaluate challenges and opportunities to improve pharmacovigilance in our setting. There are ongoing efforts to improve pharmacovigilance on the African continent with improved coordination at a national level with the support of WHO, the national regulatory authorities, and national departments of health. COVID-19 vaccine roll-out provided an opportunity to improve pharmacovigilance by integrating national vaccine platforms with active and passive surveillance including hospital and death registries.

Identifiants

pubmed: 39115010
doi: 10.1080/14740338.2024.2387322
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

J Peter (J)

Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town.
Allergy and Immunology Unit, University of Cape Town.

A Takalani (A)

Fred Hutchinson Cancer Research Center, Seattle, USA.

Jc Meyer (J)

Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.
South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.

B Semete-Makokotlela (B)

South African Health Products Regulatory Authority, Pretoria, South Africa.

S Collie (S)

Discovery, Health Intelligence, Johannesburg.

I Seocharan (I)

Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa.

A Goga (A)

HIV and Infectious Disease Research Unit, South African Medical Research Council.

N Garrett (N)

Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.

L Gail-Bekker (L)

The Desmond Tutu HIV Centre, Cape Town, South Africa.
Department of Medicine, University of Cape Town, South Africa.

G Gray (G)

South African Medical Research Council, Cape Town, South Africa.

Classifications MeSH